Tackling urgent questions in EGFRm NSCLC – 'the issue is treatment sequence'
Biomarker guidelines for non-small cell lung cancer
LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC
Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC
Targetable immune checkpoint molecules in lung cancer
Joseph Paul Eder